Zagros Pharmed Pars Pharmaceutical Company (DEDAM) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DEDAM
- Industry
- Pharmaceuticals
- Market
- Tehran Stock Exchange
Latest periods
| Item | To 1405/03/31 | To 1404/03/31 | To 1403/03/31 | To 1402/03/31 | To 1401/03/31 | To 1400/03/31 |
|---|---|---|---|---|---|---|
| Operating revenue | 2,450,961 | 2,208,112 | 2,163,725 | 1,878,845 | 1,110,312 | 834,990 |
| Cost of operating revenue | -1,495,086 | -1,084,990 | -973,243 | -858,204 | -729,341 | -431,023 |
| Gross profit (loss) | 955,875 | 1,123,122 | 1,190,482 | 1,020,641 | 380,971 | 403,967 |
| Selling, general and administrative expenses | -148,734 | -157,888 | -57,762 | -52,625 | -39,244 | -25,874 |
| Other income | 25,488 | 1,570 | 0 | 587 | 505 | 316 |
| Operating profit (loss) | 832,629 | 964,441 | 1,130,175 | 963,394 | 339,912 | 373,614 |
| Finance costs | -44,202 | -79,586 | -97,592 | -65,396 | -66,284 | -72,260 |
| Other non-operating income and expenses | -7,360 | 2,833 | 30 | 1,011 | 2,410 | 310 |
| Profit (loss) from continuing operations before tax | 781,067 | 887,688 | 1,032,613 | 899,009 | 276,038 | 301,664 |
| Current year tax | -179,645 | -160,595 | -232,338 | -204,978 | -62,026 | -72,155 |
| Net profit (loss) from continuing operations | 601,422 | 727,093 | 800,275 | 694,031 | 214,012 | 229,509 |
| Net profit (loss) | 601,422 | 727,093 | 800,275 | 694,031 | 214,012 | 229,509 |
| Net earnings (loss) per share, rials | 214 rials | 258 rials | 696 rials | 604 rials | 187 rials | 250 rials |
| Capital | 2,820,590 | 2,820,590 | 1,150,000 | 1,150,000 | 1,150,000 | 920,223 |
Reporting periods
87 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/04/01.